Cerenome, Inc. reported financial results for the second quarter ended June 30, 2026, alongside a corporate rebranding from Plus Therapeutics to Cerenome effective August 3, 2026, with its Nasdaq ticker changing to CNSY. The company posted a net loss of $9.0 million, or $1.31 per basic share, compared to a net income of $5.2 million in the prior year period. Operating expenses rose significantly due to the expansion of the CNSide commercial organization and continued funding for the REYOBIQ Phase 2 trial. Cash and investments stood at $8.6 million as of June 30, 2026. The company continues clinical development of its targeted radiotherapy candidate REYOBIQ for central nervous system cancers while expanding its CNSide diagnostic platform.